278 related articles for article (PubMed ID: 8834417)
1. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients.
Blin O; Azorin JM; Bouhours P
J Clin Psychopharmacol; 1996 Feb; 16(1):38-44. PubMed ID: 8834417
[TBL] [Abstract][Full Text] [Related]
2. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
[TBL] [Abstract][Full Text] [Related]
3. Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents.
Glick ID; Lemmens P; Vester-Blokland E
Int Clin Psychopharmacol; 2001 Sep; 16(5):265-74. PubMed ID: 11552769
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of risperidone in the long-term treatment of patients with schizophrenia.
Lindström E; Eriksson B; Hellgren A; von Knorring L; Eberhard G
Clin Ther; 1995; 17(3):402-12. PubMed ID: 7585844
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of combination of risperidone and haloperidol with divalproate in patients with acute mania.
Ouyang WC; Hsu MC; Yeh IN; Kuo CC
Int J Psychiatry Clin Pract; 2012 Sep; 16(3):178-88. PubMed ID: 22404731
[TBL] [Abstract][Full Text] [Related]
6. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.
Marder SR; Davis JM; Chouinard G
J Clin Psychiatry; 1997 Dec; 58(12):538-46. PubMed ID: 9448657
[TBL] [Abstract][Full Text] [Related]
7. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
Schooler N; Rabinowitz J; Davidson M; Emsley R; Harvey PD; Kopala L; McGorry PD; Van Hove I; Eerdekens M; Swyzen W; De Smedt G;
Am J Psychiatry; 2005 May; 162(5):947-53. PubMed ID: 15863797
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.
Alptekin K; Hafez J; Brook S; Akkaya C; Tzebelikos E; Ucok A; El Tallawy H; Danaci AE; Lowe W; Karayal ON
Int Clin Psychopharmacol; 2009 Sep; 24(5):229-38. PubMed ID: 19531959
[TBL] [Abstract][Full Text] [Related]
9. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
10. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies.
Janicak PG; Glick ID; Marder SR; Crandall DT; McQuade RD; Marcus RN; Eudicone JM; Assunção-Talbott S
J Clin Psychiatry; 2009 Jan; 70(1):25-35. PubMed ID: 19192472
[TBL] [Abstract][Full Text] [Related]
11. Risperidone in the treatment of schizophrenia.
Marder SR; Meibach RC
Am J Psychiatry; 1994 Jun; 151(6):825-35. PubMed ID: 7514366
[TBL] [Abstract][Full Text] [Related]
12. Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study.
Zhang XY; Zhou DF; Cao LY; Zhang PY; Wu GY; Shen YC
Int Clin Psychopharmacol; 2001 Nov; 16(6):325-30. PubMed ID: 11712620
[TBL] [Abstract][Full Text] [Related]
13. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
[TBL] [Abstract][Full Text] [Related]
14. Risperidone in treatment-refractory schizophrenia.
Wirshing DA; Marshall BD; Green MF; Mintz J; Marder SR; Wirshing WC
Am J Psychiatry; 1999 Sep; 156(9):1374-9. PubMed ID: 10484947
[TBL] [Abstract][Full Text] [Related]
15. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia.
Gaebel W; Riesbeck M; Wölwer W; Klimke A; Eickhoff M; von Wilmsdorff M; Jockers-Scherübl MC; Kühn KU; Lemke M; Bechdolf A; Bender S; Degner D; Schlösser R; Schmidt LG; Schmitt A; Jäger M; Buchkremer G; Falkai P; Klingberg S; Köpcke W; Maier W; Häfner H; Ohmann C; Salize HJ; Schneider F; Möller HJ;
J Clin Psychiatry; 2007 Nov; 68(11):1763-74. PubMed ID: 18052570
[TBL] [Abstract][Full Text] [Related]
16. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
[TBL] [Abstract][Full Text] [Related]
17. Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial.
Heck AH; Haffmans PM; de Groot IW; Hoencamp E
Schizophr Res; 2000 Dec; 46(2-3):97-105. PubMed ID: 11120421
[TBL] [Abstract][Full Text] [Related]
18. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Risperidone Study Group.
Peuskens J
Br J Psychiatry; 1995 Jun; 166(6):712-26; discussion 727-33. PubMed ID: 7545060
[TBL] [Abstract][Full Text] [Related]
19. A naturalistic comparison study of the efficacy and safety of intramuscular olanzapine, intramuscular haloperidol, and intramuscular levomepromazine in acute agitated patients with schizophrenia.
Suzuki H; Gen K; Takahashi Y
Hum Psychopharmacol; 2014 Jan; 29(1):83-8. PubMed ID: 24424709
[TBL] [Abstract][Full Text] [Related]
20. Intranasal oxytocin as an adjunct to risperidone in patients with schizophrenia : an 8-week, randomized, double-blind, placebo-controlled study.
Modabbernia A; Rezaei F; Salehi B; Jafarinia M; Ashrafi M; Tabrizi M; Hosseini SM; Tajdini M; Ghaleiha A; Akhondzadeh S
CNS Drugs; 2013 Jan; 27(1):57-65. PubMed ID: 23233269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
